Últimas noticias sobre CervoMed (NASDAQ:CRVO) Bolsa

CervoMed

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

CervoMed Inc

Billionaire investor Warren Buffett cut several of Berkshire Hathaway Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) <a href="https://www.benzinga.com/markets/equities/24/08/40232279/is-warren-buffett-bearish-or-waiting-to-pounce-berkshire-now-owns-more-t-bills-than-federal-rese">largest holdings this year</a>. 
The Omaha, Nebraska-based holding company&#8217;s latest 13F filing shows that the sell-off trend continues.
What Happened: Berkshire&#8217;s latest 13F filing, filed on Thursday, reflects the company&#8217;s largest holdings as of September 30.
Buffett reduced his stake in Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from 400 million to 300 million shares. Thus, Berkshire has now cut its position in the Cupertino, California-based tech giant by over two-thirds since 2023&#8217;s third quarter.
The Omaha &#8220;oracle&#8221; also continued to cut his stake in Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), trimming back another 23% of Berkshire&#8217;s position.
Berkshire cut nearly all of its position in Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>). Buffett <a href="https://www.benzinga.com/markets/equities/24/08/40385824/warren-buffett-still-holds-400m-apple-shares-reveals-new-investments-in-ulta-beauty-and-heico-el">revealed a position in the cosmetic store chain</a> in August; the company&#8217;s stock has performed roughly even since then. Buffett&#8217;s Ulta holding period was unusually short for the famed value investor.
Meanwhile, Buffett added a couple of fresh faces to Berkshire&#8217;s portfolio.
Buffett bought 1,277,256 shares of Ann Arbor, Michigan-based pizza chain Domino&#8217;s Pizza Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>). He also made a foray into pool equipment, buying 404,057 shares of Pool Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>).
Price Action: Investors quickly reacted to Berkshire&#8217;s 13F filing after hours:
<ul>
<li>Dominoes Pizza shares traded up nearly 7%.</li>
<li>Pool Corp shares traded up nearly 6%.</li>
<li>Ulta Beauty shares fell over 4%.</li>
<li>Apple and Bank of America shed insignificant portions of their market value.</li>
</ul>
Why it Matters: During Berkshire&#8217;s annual shareholder meeting in May, Buffett hinted that his sell-offs were a result of tax implications. 
This <a href="https://www.benzinga.com/markets/equities/24/08/40385824/warren-buffett-still-holds-400m-apple-shares-reveals-new-investments-in-ulta-beauty-and-heico-el">has not stopped</a> investors&#8217; conjecture that Buffett is perhaps bearish <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">on the market at large</a>.
Alternatively, Buffett could be simply trimming positions that take up an outsized portion of Berkshire&#8217;s portfolio to reduce exposure.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Image via Flickr

Equities

News

AAPL

POOL

ULTA

Warren Buffett's Berkshire Hathaway Slashes Apple, BofA Holdings, Adds Domino's Pizza In Q3

WIIM

LGCY

Legacy Education shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent.

Earnings

Earnings Beats

BNTC

Benitec Biopharma Q1 2025 GAAP EPS $(0.48) Beats $(0.55) Estimate

MLSS

Milestone Scientific shares are trading higher after the company reported better-than-expected Q3 financials.

Hedge Funds

General

MRCY

Starboard Value's Q3 2024 13F Filing Reveals Complete Exits From Mercury Systems With 2.29M Shares, AECOM With 625K Shares

BENF

Beneficient shares are trading higher after the company reported a year-over-year increase in Q2 revenue results.

OPTX

Syntec Optics Holdings Q3 EPS $0.00 Down From $0.01 YoY, Sales $7.86M Up From $6.6M YoY

Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest <a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957424006690/xslForm13F_X02/infotable.xml">Form 13F</a> on Thursday and disclosed its trading activity from the prior quarter. Here's a look at Tiger Global's <a href="https://www.benzinga.com/opinion/24/08/40422936/steal-these-two-stock-ideas-from-the-best-investors-in-the-world">portfolio changes.&nbsp;</a>
The Details: Tiger Global has $23.439 billion in assets under management and made no changes to its top five holdings:&nbsp;
<ul>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) </li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) </li>
<li>Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) </li>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) </li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) </li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
New Positions: Tiger Global opened three new positions including a $801.3 million stake in Flutter Entertainment Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), the parent company of FanDuel. The fund also opened a $201.4 million position in Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) and a $48.9 million position in South Korean e-commerce platform Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>). 
Notable Trades: Tiger Global added 564,090 shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to its portfolio, bringing its total number of shares owned to 3,634,980. The fund also increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) by 195,714 shares, bringing its current holdings to 5,839,256 shares valued at $897.5 million. 
Closed Positions: The hedge fund closed out its positions in Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) and DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image created using artificial intelligence via MidJourney.

Movers

ALAB

CPNG

DXCM

FLUT

GOOGL

MSFT

TTWO

Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom

RVYL

Ryvyl shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY24 sales guidance.

BLMN

GDDY

Starboard Value's Q3 2024 13F Filing Shows Reduced Stakes In GoDaddy By 32% To 3.13M Shares, Salesforce By 14% To 1.44M Shares, Humana By 62% To 191K Shares, And Bloomin' Brands By 14%

Trading Ideas

AMZN

Third Point 13F Shows Decreased Stake In PG&E Corp By 7% From 53,750,000 To 49,750,000 Shares; Amazon By 27% From 5,100,000 To 3,700,000 Shares; Danaher Corp By 5% From 2,050,000 To 1,950,000 Shares; Vistra Corp By 29% From 4,470,000 To 3,175,000 Shares; Microsoft By 45% From 1,580,000 To 870,000 Shares; Meta Platforms By 50% From 1,100,000  To 545,000 Shares; TSM By 12% From 2,025,000 To 1,780,000 Shares; Apple By 52% From 1,950,000 To 930,000 Shares; Amphenol Corp By 43% From 2,800,000 To 1,600,000 Shares

AISP

Airship AI shares are trading lower after the company reported worse-than-expected Q3 revenue results.

ADSK

MTCH

Starboard Value's Q3 2024 13F Filing Reveals New Stakes In Autodesk With 1.85M Shares, Match Group With 9.56M Shares

SEC Chairman Gary Gensler on Thursday defended his regulatory approach to crypto markets, emphasizing investor protection and compliance, as he hinted at an end of his stint as <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41883348/donald-trump-cant-fire-gary-gensler-but-pro-crypto-policies-means-industry-is-on-the-verge-of-a-golden-era">the agency&#8217;s chair</a>.
What Happened: In his remarks at the Practicing Law Institute&#8217;s 56th Annual Institute on Securities Regulation, Gensler <a href="https://www.sec.gov/newsroom/speeches-statements/gensler-remarks-pli-s-56th-annual-institute-securities-regulation-111424">noted</a> that his agenda builds on the SEC's history of oversight in crypto, referencing cases like Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), and emphasized the consistency of the Commission's actions over the years.
He said that since 2018, around 5-7% of SEC enforcement has been directed toward digital assets, maintaining that the agency&#8217;s approach targets specific non-compliant participants rather than the entire crypto market. 
He affirmed that "court after court" has upheld the SEC's jurisdiction over offerings that involve securities, even in digital forms.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41985685/investor-loses-25m-due-to-misplaced-crypto-transfer-says-cexs-feel-more-secure">Investor Loses $25M Due To Misplaced Crypto Transfer, Says CEXs Feel More Secure</a>
"Everything we've done is focused on ensuring compliance with our laws," Gensler said. 
He added that investor protection, through disclosure and oversight, has been a central priority, adding that compliance fosters market trust. 
Highlighting the SEC's endorsement of Bitcoin futures ETFs in 2021 and later Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) products, Gensler claimed these regulated products provided benefits such as lower fees and enhanced transparency, distinguishing them from the broader crypto markets.
His also noted that while Bitcoin, Ether, and stablecoins comprise a large portion of the crypto market, other assets—often speculative—had yet to demonstrate enduring use cases.
Gensler closed with thanking the team at the Securities and Exchange Commission, emphasizing it has been a &#8220;great honor to serve with them, doing the people's work and ensuring that our capital markets remain the best in the world.&#8221;
What&#8217;s Next: As Gensler&#8217;s term draws to a close, his approach remains influential. His remarks come as the digital asset community gathers insights at events like Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> conference on Nov. 19, where regulatory and innovation discussions continue to unfold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41984505/bitcoin-to-peak-at-180000-says-vanecks-head-of-digital-assets-research">Bitcoin To Peak At $180,000, Says VanEck&#8217;s Head Of Digital Assets Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Gary Gensler Hints At Ending His Stint As SEC Chair, Defends Crypto Regulation Agenda

ONCT

Oncternal Therapeutics Announced Workforce Reduction Effective December 2, 2024; Four Employees Will Remain In A Part-time Capacity In Connection With Exploration Of Strategic Alternatives; Expects $2.4M In Charges From Workforce Reduction

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target

Third Point 13F Shows Increased Stake In Intercontinental Exchange By 109% From 1,000,000 To 2,085,000 Shares; Live Nation Entertainment By 71% From 1,365,000 To 2,340,000 Shares; CRH By 215% From 650,000 To 2,050,000 Shares; Telephone & Data Systems By 27% From 2,266,060 To 2,875,000 Shares

Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.87) by 3.45 percent.

Kodiak Sciences Q3 2024 GAAP EPS $(0.84) Beats $(0.87) Estimate

Offerings

Associated Banc-Corp Announces Proposed Common Stock Offering Of 11.5M Shares

ANSS

FERG

LPLA

TSLA

Third Point 13F Shows Added Stake In Brookfield Corp With 4,725,000 Shares; Ferguson Enterprises With 965,000 Shares; Flutter Entertainment With 510,000 Shares; LPL Financial Holdings With 485,000 Shares; Carpenter Technology With 660,000 Shares; Tesla With 400,000 Shares; CVS Health Corp With 1,575,000 Shares; Ansys With 255,000 Shares; Hawaiian Electric Industries With 1,535,000 Shares; Clear Channel Outdoor Holdings With 850,000 Shares

CervoMed (CRVO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTradin...

CervoMed: A Strong Buy on Pioneering DLB Treatment and Solid Financial Footing

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on CervoMed (CRVO – Research Report) today and set a price target of $35.00. The compan...

Morgan Stanley Sticks to Their Buy Rating for CervoMed (CRVO)

CervoMed (CRVO) just unveiled an update. Cervomed has released key information about its business operations, clinical studies, and financial statu...

CervoMed Updates Investors on Business and Clinical Progress

Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on CervoMed (CRVO – Research Report). The associated price target rem...

CervoMed's Neflamapimod Shows Promise in DLB: A Buy Rating with a $65 Price Target

The latest update is out from CervoMed ( ($CRVO) ). CervoMed Inc. had an agreement in place to sell up to $20 million of its common stock through B...

CervoMed Ends $20 Million Stock Sales Agreement with BTIG

CervoMed files for $250M mixed securities shelf

Analyst Sumant Kulkarni of Canaccord Genuity maintained a Buy rating on CervoMed (CRVO – Research Report), retaining the price target of $65.00. Su...

CervoMed's Neflamapimod: A Promising Phase 2b Trial for Addressing Dementia with Lewy Bodies

CervoMed (CRVO) announced key takeaways from two oral presentations characterizing the potential of neflamapimod as a treatment for patients with d...

CervoMed announces key takeaways from presentations on neflamapimod

Reports Q3 revenue $1.94M, consensus $3.07M. "In the third quarter, we conducted the final patient visits in RewindD-LB, our Phase 2b trial evaluat...

CervoMed reports Q3 EPS (55c), consensus (41c)

Cervomed Inc. ( ($CRVO) ) has released its Q3 earnings. Here is a breakdown of the information Cervomed Inc. presented to its investors. CervoMed I...

CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials

CRVO

Press Releases

CervoMed to Participate in Upcoming Investor Conferences

Health Care

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Comments

CervoMed

Noticias

Últimas noticias sobre CervoMed (NASDAQ:CRVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL